ClinicalTrials.gg

Program

SM17

Also written as “SM17 for injection”.

Its studies are mostly in Dermatitis, Atopic · Asthma, led by SinoMab BioScience.

Furthest: phase 1, since Mar 31, 20223 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
SinoMab BioScience30 open or runningphase 1since Mar 31, 2022Mar 31, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 31, 2022First study: phase 1 study in AsthmaFirst studyNCT05332834 · 77 enrolled · United States
  2. Jul 21, 2025Phase 1 study in Dermatitis, AtopicNCT07103369 · 64 enrolled · China
  3. Mar 3, 2026Phase 1 study in Dermatitis, AtopicNCT07466940 · 30 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07466940Dermatitis, Atopic · China1CompletedFeb 3, 202630
NCT07103369Dermatitis, Atopic · China1CompletedMar 24, 202564
NCT05332834Asthma · United States1CompletedSep 26, 202377

How it is read

Names in the registry

  • “SM17”, 2 entries
  • “SM17 for injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.